Fortitude Family Office’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Fortitude Family Office’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-74	Closed	-$9.76K	–	2165
2025 Q1	$9.76K	Sell	74 -11	-13%	-$1.37K	﹤0.01%	541
2024 Q4	$7.1K	Hold	85	–	–	﹤0.01%	730
2024 Q3	$6.22K	Buy	85 +11	+15%	+$827	﹤0.01%	717
2024 Q2	$5.07K	Hold	74	–	–	﹤0.01%	584
2024 Q1	$5.12K	Hold	74	–	–	﹤0.01%	599
2023 Q4	$5.3K	Buy	+74	New	+$4.26K	﹤0.01%	600

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Fortitude Family Office's ITCI Position: Q2 2025 in Review

Fortitude Family Office sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 74 shares — an estimated $9.76K sold.

Fortitude Family Office first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $9.76K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Fortitude Family Office reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Fortitude Family Office sold 74 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $9.76K.
Fortitude Family Office first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
Fortitude Family Office's Intra-Cellular Therapies Inc. position peaked at $9.76K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Fortitude Family Office's 13F filing for Q2 2025, filed 15 Jul 2025.